Cipla-backed Stempeutics, an Indian advanced clinical stage biotech company based in Bangalore, said it is the first company in the world to be granted a process patent by the State Intellectual Property Office of China for a stem cell drug treatment based on pooling technology that could potentially be used in the treatment of critical limb ischemia.
Sumitomo Dainippon Pharma said the results of Phase III clinical trials for its Latuda schizophrenia treatment in Japan disappointed and it would evaluate the next steps forward, but noted that a separate clinical trial on a bipolar disorder candidate would proceed.
China got international plaudits on the recent World Malaria Day not so much for handling its own cases of the disease but for providing the world with what one expert called "the best" treatment, artemisinin-based combination therapies.
China's FDA is laying plans to work directly with its U.S. counterpart to learn the secrets of drug and medical-device regulation and bring China drug-making and other regulated industries up to international standards.
China's cabinet, the State Council, has circulated a proposal to tighten up the practice of using insiders and others as intermediaries to get access to drug and other regulators and their approval processes.
Bristol-Myers Squibb's immuno-oncology med Opdivo is racking up positive data and earning regulatory gold stars in record time. Now, the drug is poised to gain even more ground after the European Medicines Agency gave Opdivo its marketing thumbs-up as a first-line treatment for advanced melanoma--an approval it has yet to earn in the U.S.--and in previously treated patients.
Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.
India's drug minister said there was a misconception in the nation--including in its media--that prices of pharmaceuticals had skyrocketed recently. Ananth Kumar noted that 350 additional drugs had been brought under price controls in the past 10 months and other plans are already driving down costs.
China researchers have confirmed widespread rumors circulating in the scientific community that they had performed landmark work using a gene-editing technique on human embryos--usually an ethical no-no. Regardless of the debate surrounding the work, they concluded that what they were attempting was not feasible.
Boehringer Ingelheim already had the FDA's "breakthrough" designation on idarucizumab, an antidote to its blockbuster anticoagulant Pradaxa. Now, the reversal agent has stepped on the agency's fast track, which cuts review time by four months.